NEXT Financial Holdings’s Neurocrine Biosciences NBIX Stock Holding History

NEXT Financial Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$26K	Buy	+295	New	+$24.7K	0.01%	896

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NEXT Financial Holdings's NBIX Position: Q1 2019 in Review

NEXT Financial Holdings opened a new position in Neurocrine Biosciences (NBIX) in Q1 2019: 295 shares worth $26K. The stake represents 0.01% of the portfolio and ranks #896 among its holdings.

325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

NEXT Financial Holdings held 295 shares of Neurocrine Biosciences worth $26K as of Q1 2019.
Neurocrine Biosciences was a new NEXT Financial Holdings position in Q1 2019.
Neurocrine Biosciences made up 0.01% of NEXT Financial Holdings's portfolio in Q1 2019, its #896 holding.
325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on NEXT Financial Holdings's 13F filing for Q1 2019, filed 13 May 2019.